Use of off-label nephrology-related drugs in hospitalized pediatric patients: a retrospective study

详细信息    查看全文

• 作者：Marchella Yasinta ; Ruo-Chen Che ; Cai-Yu Hu ; Xiang-Hui Du…
• 关键词：in ; patient ; kidney ; off ; label drug ; pediatrics
• 刊名：World Journal of Pediatrics
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：12
• 期：2
• 页码：236-242
• 全文大小：215 KB
• 参考文献：1.Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320:79–82.PubMed
  2.Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med 2008;358:1427–1429.CrossRef PubMed
  3.Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 2009;34:277–287.CrossRef PubMed
  4.Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003;17:125–131.CrossRef PubMed
  5.Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf 2002;25:1–5.CrossRef PubMed
  6.Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L, et al. Pediatric off-label drug use in China: risk factors and management strategies. J Evid Based Med 2013;6:4–18.CrossRef PubMed
  7.Olsson J, Kimland E, Pettersson S, Odlind V. Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care-a nationwide study. Acta Paediatr 2011;100:1272–1275.CrossRef PubMed PubMedCentral
  8.Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, et al. Stimulation programs for pediatric drug research-do children really benefit? Eur J Pediatr 2007;166:849–855.CrossRef PubMed PubMedCentral
  9.Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007;161:282–290.CrossRef PubMed
  10.Kieran EA, O’Callaghan N, O’Donnell CP. Unlicensed and off-label drug use in an Irish neonatal intensive care unit: a prospective cohort study. Acta Paediatr 2014;103:e3–e4.CrossRef
  11.Ye WQ, Liang Y, Cui YM, Ding J. Survey on common pediatric drugs for renal diseases. Zhonghua Er Ke Za Zhi 2013;51:888–891. [In Chinese]PubMed
  12.Silva D, Ansotegui I, Morais-Almeida M. Off-label prescribing for allergic diseases in children. World Allergy Organ J 2014;7:4.CrossRef PubMed PubMedCentral
  13.Wan ZL, Zhuo FX, Xie RZ, Quan CR, Liao YF. Intervention of Clinical Pharmacists on the Irrational Drug Use in Oncology Department. Anti-tumor Pharmacy 2014;4:389–392. [In Chinese]
  14.Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358–363.CrossRef PubMed PubMedCentral
  15.Hedberg A, Fismen S, Fenton KA, Fenton C, Osterud B, Mortensen ES, et al, Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 2011;63:1065–1075.CrossRef PubMed
  16.Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 2006;10:268–273.CrossRef PubMed
  17.Benck U, Haeckel S, Clorius JH, van der Woude FJ. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system. Clin J Am Soc Nephrol 2007;2:58–67.CrossRef PubMed
  18.Sanghvi A, Warty VS, Diven WF, Todo S, Starzl T. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. Transplant Proc 1989;21:1050–1052.PubMed PubMedCentral
  19.Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008;23:910–913.CrossRef PubMed
  20.Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004;19:281–287.CrossRef PubMed
  21.Tsugawa K, Tanaka H, Nakahata T, Ito E. Effective therapy of a child case of refractory nephrotic syndrome with tacrolimus. Tohoku J Exp Med 2004;204:237–241.CrossRef PubMed
  22.Lombel RM, Hodson EM, Gipson DS, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 2013;28:409–414.CrossRef PubMed
  23.Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013;28:415–426.CrossRef PubMed
  24.Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999;33:680–682.CrossRef PubMed
  25.Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002;41:381–388.CrossRef PubMed
  26.Gupta SK, Benet LZ. High-fat meals increase the clearance of cyclosporine. Pharm Res 1990;7:46–48.CrossRef PubMed
  27.Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002;24:330–350; discussion 29.CrossRef PubMed
  28.Xue W, Song Y, Tian P, Ding X, Pan X, Yan H, et al. The effects of diltiazem in renal transplantation patients treated with cyclosporine A. J Biomed Res 2010;24:317–323.CrossRef PubMed PubMedCentral
  29.Tan E, Cranswick NE, Rayner CR, Chapman CB. Dosing information for paediatric patients: are they really “therapeutic orphans”? Med J Aust 2003;179:195–198.PubMed
  30.Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther 2012;91:796–801.CrossRef PubMed
  31.Ribeiro M, Jorge A, Macedo AF. Off-label drug prescribing in a Portuguese paediatric emergency unit. Int J Clin Pharm 2013;35:30–36.CrossRef PubMed
  32.Mühlbauer B, Janhsen K, Pichler J, Schoettler P. Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. Dtsch Arztebl Int 2009;106:25–31.PubMed PubMedCentral
  33.Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, et al. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol 2005;61:775–779.CrossRef PubMed
  34.’t Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Strickerf BH. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J 2004;23:310–313.CrossRef PubMed
  
• 作者单位：Marchella Yasinta (1) (2)
  Ruo-Chen Che (1) (2)
  Cai-Yu Hu (1) (2)
  Xiang-Hui Du (1) (2)
  Gui-Xia Ding (1) (2)
  Song-Ming Huang (1) (2)
  Ying Chen (1) (2) (3)
  Ai-Hua Zhang (1) (2)
  
  1. Department of Nephrology, Nanjing Children’s Hospital Affiliated to Nanjing Medical University, Nanjing, China
  2. Jiangsu Key Laboratory of Pediatrics, Nanjing, China
  3. Department of Nephrology, Nanjing Children’s Hospital Affiliated to Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210029, China
  
• 刊物主题：Pediatrics; Pediatric Surgery; Maternal and Child Health; Intensive / Critical Care Medicine; Surgery; Imaging / Radiology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1867-0687

文摘

Background The information about the use of off-label drugs in pediatric nephrology is still lacking, which leads to increased adverse reactions and medical disputes. We retrospectively analyzed the use of off-label drugs in the in-patient ward of the nephrology department of Nanjing Children’s Hospital, China in order to provide more complete information about the use of drugs for children.